Unforgettable #EANO2025 meeting wrapping up today in Prague. See you next year!

🚨 Big news from #EANO2025! Final #CATNON results show adding 12 cycles of temozolomide after radiotherapy doubles survival in IDH-mutant anaplastic astrocytoma: 12.5 vs 6 years. A global academic effort in rare cancers. 🔗Full story: https://t.co/b0YtBpHeEk @EANOassociation

📢 @EANOassociation 2025 kicks off today in Prague! Proud to see strong #EORTC representation with six abstracts and a joint session with BTG featuring EORTC-led projects on clinical trial planning. More info 👉 https://t.co/KQmVoNDQHP #EANO2025 #NeuroOncology #CancerResearch

Il saluto di In altre parole a Paolo Sottocorona. La buonanotte di Massimo Gramellini https://t.co/B8ICE2V3tm

Medici e infermieri in crisi: «Uno su tre è depresso, uno su dieci pensa al suicidio». Allarme dell'Oms sulla salute mentale

Oggi ho concluso il #dottorato. Un capitolo rimasto aperto durante momenti intensi ma anche difficili. Eppure grata, perché è stato il periodo in cui ho accolto Giacomo nella mia vita. E avanti.

Today I completed my #PhD. A chapter that had stayed open through intense but also difficult times. Yet I am grateful, because during this period, little Giacomo came into my life. Let's move forward.

3 inspiring lectures at the Masterclass in #Neuroncology @ Padova 📍 Longitudinal sampling: a new frontier in GBM treatment – @EAChiocca 📍 Overcoming, bypassing & disrupting the BBB – Ahmed Idbahi 📍 A bridge over troubled waters: making vaccines work in GBM – David Reardon

Final Update CATNON ASCO 2025 · Median F/U 11 yrs · NO sig benefit concurrent TMZ · Sig benefit (HR 0.54) Adjuvant TMZ in IDHm (median OS 12.5 years) · NO benefit w/TMZ for IDHwt

We are grateful to our ~44,000 attendees who made #ASCO25 a success & the place to be! With nearly 40% joining us from outside the U.S., we are truly a global community united by our shared goal of improving #CancerCare & pt outcomes around the world. A heartfelt ‘thank you.’ 💗

Bispecific antibodies, which can target 2 antigens or pathways at once, are being used more frequently in cancer care. An Ed Session later this morning at #ASCO25 (11:30AM, Rm S406) will discuss their role in treatment + potential adverse events: https://t.co/QVv9FMtsXN @curijoey

These posters represent just some of the #cancerresearch conducted worldwide. #impressive #unitedbycancerresearch #ASCO25

Heading to Chicago - truly honoured to see the REGOMA-2 study recognized at #ASCO25 @DrLombardiGiu Thanks @ConquerCancerFd

Ti ho visto "pellegrino penitente" nell'#Iraq a cui nessuno prima di te, incolpevole, aveva chiesto scusa. E tra i profughi di #Lesbo. Te ne vai nel momento in cui abbiamo più bisogno. Chi chiamerà tutte le sere #Gaza? Senza meritarlo, seguiremo il tuo esempio #PapaFrancesco

Bar, ore 10:21. A: "A vago stare in America, desso che ghe xe trump che sistema tutto. " B: "A'l voe mandarte su marte." A: "I clandestini, no mi."

New year, new people, new hopes #2025

Stanchi e malpagati, la metà dei medici e degli infermieri è in burnout - la Repubblica

The immune response

It's the International Brain Tumour Awareness Week! @theIBTA @ERN_EURACAN is dedicated to improving care for those affected by brain tumours.🧠 📅This week, take a moment to learn about brain tumour symptoms, share information, and support research efforts.

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 #Oligodendroglioma: https://t.co/T4K4N9YVNp #btsm